Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 6/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | HTR7 | P34969 | 2/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.35 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8518566 | 0.91 | CCR2 (0.45) | CCR2HRH3ACHEADORA2AADORA1 | |
| SCHEMBL7156694 | 0.88 | CCR2 (0.61) | CCR2HRH3ACHECHEK2TBK1 | |
| SCHEMBL7554497 | 0.86 | CCR2 (0.54) | CCR2HRH3ACHEADORA2AADORA1 | |
| SCHEMBL7151726 | 0.86 | CCR2 (0.40) | CCR2ACHEADORA2AADORA1CHEK2 | |
| SCHEMBL7159244 | 0.85 | CCR2 (0.51) | CCR2HRH3ACHEADORA2AADORA1 | |
| SCHEMBL7554509 | 0.84 | CCR2 (0.56) | CCR2HRH3ACHEADORA2AADORA1 | |
| SCHEMBL7549560 | 0.82 | CCR2 (0.56) | CCR2HRH3ACHEHTR7CYP1A2 | |
| SCHEMBL8519529 | 0.82 | CCR2 (0.55) | CCR2HRH3ACHECHEK2TBK1 | |
| SCHEMBL7549699 | 0.82 | CCR2 (0.60) | CCR2HRH3ACHECYP1A2CYP2D6 | |
| SCHEMBL8404117 | 0.81 | CCR2 (0.37) | CCR2ACHEADORA2AADORA1TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6534521-B2 | Useful in the treatment of inflammation, atherosclerosis, restenosis, and immune disorders such as arthritis and transplant rejection | MILLENNIUM PHARMACEUTICALS, INC. | 2003-03-18 | — | — | US | disclosed |
| US-20020099054-A1 | 2-phenyl benzimidazole derivatives as MCP-1 antagonists | WARNER-LAMBERT COMPANY (US) | 2002-07-25 | — | — | US | disclosed |
| US-6348487-B1 | ANTIINFLAMMATORY AGENTS, ATHEROSCLEROSIS, RESTINOSIS AND IMMUNE DISORDERS | MILLENNIUM PHARMACEUTICALS, INC. | 2002-02-19 | — | — | US | disclosed |
| US-6184235-B1 | MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1) ANTAGONIST FOR TREATMENT OF INFLAMMATORY DISEASES, ATHEROSCLEROSIS, RESTENOSIS, AUTOIMMUNE DISEASES, ORGAN TRANSPLANT REJECTION IN MAMMALS | WARNER-LAMBERT COMPANY | 2001-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099054-A1 | 2-phenyl benzimidazole derivatives as MCP-1 antagonists | CCR1, CCR2, CCR8 | CCR2 2/4885HRH3 165/4885ACHE 4652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.